TITLE

Other News To Note

PUB. DATE
April 2013
SOURCE
BioWorld Today;4/11/2013, Vol. 24 Issue 69, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers world news briefs in 2013. Aeterna Zentaris Inc. signs a profit-sharing and co-development agreement with contract clinical development organization Ergomed Clinical Research Ltd. The U.S. National Institute of Allergy and Infectious Diseases will grant $3.5 million to Inovio Pharmaceuticals Inc. Omeros Corp. reports its preclinical data indicating that its GPR17-targeting compounds improves function from experimental autoimmune encephalomyelitis.
ACCESSION #
87637995

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;9/15/2011, Vol. 22 Issue 179, p7 

    This section offers news briefs on biotechnological research as of September 15, 2011. The U.S. Food and Drug Administration (FDA) has provided clearance to AB Science SA for investigational new drug application for an anti-asthmatic drug. Aeterna Zentaris Inc. reported final Phase II data for...

  • Financings Roundup.  // BioWorld Today;4/19/2010, Vol. 21 Issue 74, p5 

    The article unveils the plan of AEterna Zentaris Inc. to sell 15 million worth of securities to institutional investors.

  • AETERNA ZENTARIS INC.  // MondayMorning;11/14/2011, Vol. 19 Issue 41, p13 

    The article reports that Aeterna Zentaris Inc. of Quebec, Canada had a third-quarter profit attributed to a higher net finance income and a revenue increase brought about by its hormone drug Cetrotide.

  • AACR 2012.  // BioWorld Today;4/4/2012, Vol. 23 Issue 65, p3 

    The article relates that Aeterna Zentaris Inc. has reported that orally active PI3K/Erk 1/2 inhibitor AEZS-13g displayed inhibition and activity against PI3k and Erk signaling pathways in more than 40 human tumor cell lines.

  • Financings Roundup.  // BioWorld Today;5/23/2013, Vol. 24 Issue 99, p3 

    The article announces that drug maker Aeterna Zentaris Inc. and investment bank MLV and Co. LLC entered into an at-the-market sales agreement for the sale of 2.5 million common shares on Nasdaq.

  • FINANCINGS.  // BioWorld Today;8/1/2013, Vol. 24 Issue 146, p7 

    The article reports on the announcement by biotechnology firm Aeterna Zentaris Inc. that it has completed its registered direct offering of 7.8 million U.S. dollars of units comprising common shares and common share purchase warrants to certain institutional investors.

  • Untitled.  // BioWorld Today;11/26/2013, Vol. 24 Issue 228, p4 

    The article reports on the initial public offering (IPO) closed by Aeterna Zentaris Inc., in November 2013.

  • Clinic Roundup.  // BioWorld Today;6/22/2012, Vol. 23 Issue 121, p9 

    The article offers news briefs on clinical trials in the biotechnology industry including the results of the Phase I trial of the oral PI3K/Akt inhibitor perifosine from Aeterna Zentaris Inc., the results of Phase III studies of the drug Northera from Chelsea Therapeutics, and the agreement...

  • Clinic Roundup.  // BioWorld Today;10/19/2012, Vol. 23 Issue 204, p7 

    This article presents updates on several clinical trials as of October 19, 2012, which include Aeterna Zentaris Inc.'s ghrelin agonist AEZS-130, Genticel SA's ProCervix vaccine and Novavax Inc.'s A/H5N1 avian influenza vaccine.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics